Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quavonlimab + Pembrolizumab in Advanced Solid Tumors
NCT03179436Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2017
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, open-label trial of quavonlimab in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 1 more (12 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With ≥1 Dose Limiting Toxicity up to 6 weeks, Number of Participants With ≥1 Adverse Event up to 77 months and 2 more. Started Jul 2017; status: completed.
02
Drugs
quavonlimab
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)melanoma
Beyond the preview
Go deeper on NCT03179436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179436.